Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Closed Research Teams
  • View item
  • Home
  • ICR Divisions
  • Closed Research Teams
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer

Thumbnail
Date
2010-10
ICR Author
Cooper, Colin
Author
Kudahetti, SC
Fisher, G
Ambroisine, L
Prowse, D
Kattan, MW
Foster, CS
Moller, H
Oliver, T
Fletcherk, A
Cooper, C
Reuter, V
Scardino, P
Cuzick, J
Berney, DM
Grp, TP
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Aims: Treatment decisions are difficult in clinically localised prostate cancer and further biomarkers of aggressive behaviour are required. We investigated the hypothesis that the tissue expression of three cell cycle markers, Rb, p21 and p16, would provide helpful prognostic information in a well characterised series of prostate cancers which were clinically localised and treated conservatively. Methods: The immunohistochemical staining expression of these markers was assessed in tissue microarrays and correlated with 10 year prostate cancer survival and overall survival and then compared with pathological data including contemporary Gleason score, age, measures of tumour extent and initial serum prostate specific antigen (PSA) level. Results: Rb overexpression did not show any significant association with Gleason score or prostate cancer survival. p21 protein expression showed a significant association with prostate cancer survival (p = 0.02) and overall survival (p = 0.01) in a univariate model but not in a multivariate model with pathological and serum PSA data. There was a significant association between p16 cytoplasmic expression and prostate cancer survival (HR = 2.52, 95% CI = 1.79-3.55, p < 0.001) and overall survival (HR = 1.54, 95% CI = 1.20-1.98, p = 0.001) in a univariate model. p16 expression remained an independent prognostic factor for prostate cancer survival (HR = 1.50, 95% CI = 1.05-2.14, p = 0.03). Conclusion: We conclude that p16 cytoplasmic expression can be used as a predictor of outcome in conservatively treated prostate cancer. Rb and p21 show no independent association with outcome and therefore further research is not warranted.
URI
https://repository.icr.ac.uk/handle/internal/2353
DOI
https://doi.org/10.3109/00313025.2010.508788
Collections
  • Closed Research Teams
Research team
Cell Transformation
Language
eng
License start date
2010-10
Citation
PATHOLOGY, 2010, 42 pp. 519 - 523
Publisher
TAYLOR & FRANCIS LTD

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.